NCT06625775 2026-03-18Open-Label Study of BBO-10203 in Subjects With Advanced Solid TumorsTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)Phase 1 Recruiting392 enrolled
NCT06506955 2026-03-11Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.Taiho Oncology, Inc.Phase 2/3 Enrolling by invitation15 enrolled